Food and Drug Administration - Search News

FDA Approves 1st Non-Opioid Pain Medicine in 20 Years

CNN on MSN · 3h

FDA approves first new type of pain medication in 25 years

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose.

The Associated Press on MSN · 7h

FDA approves painkiller designed to eliminate the risk of addiction associated with opioids

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.

The Washington Post · 8h

FDA approves new, non-opioid painkiller Journavx

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

FDA, Axsome and migraine

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

Business Insider · 10h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Investing.com on MSN · 9h

FDA approves new migraine treatment SYMBRAVO

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®,

type 2 diabetes, chronic kidney disease and FDA

CNN on MSN · 2d

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

U.S. News & World Report · 1d

FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes

Doctors already use Ozempic to manage type 2 diabetes and reduce the risk of heart disease in patients with diabetes. This move, as reported by The Times, was based on research sh

FDA issues Class I on Lay's potato chips

Newsweek on MSN · 1d

Broccoli Recall Update as FDA Sets Highest Risk Level Over Bacteria Fears

Broccoli florets sold in Walmart stores across 20 states that were recalled over bacterial contamination fears have been given the U.S. Food and Drug Administration (FDA)'s highest risk level.

Fortune on MSN · 1d

FDA reclassifies Lay’s potato chips recall to the highest risk level, warning the chips could cause ‘serious adverse health consequences or death’

The FDA has raised the risk level on a recall of Lay’s potato chips to the highest level, warning the recalled product could cause death. The chips were originally recalled last month for containing undeclared milk.

Austin American-Statesman on M… · 1d

Put down the bag of chips: FDA issues Class I on Lays potato chips for undeclared allergen

According to the FDA, If consumers have an allergy or sensitivity to milk, they should not consume the product and discard it immediately.

12h

US FDA Identifies Cybersecurity Risks in Certain Patient Monitors

(Reuters) - The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks ...

2don MSN

Trump admin's FDA withdraws proposed federal rule to ban menthol cigarettes

Trump's FDA moved to squash a proposed rule to ban menthol cigarettes just one day after the president was sworn in, angering ...

11hOpinion

Do food warning labels actually work? Answering your questions.

Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results